Supriya Lifescience Ltd
Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic.[1]
- Market Cap ₹ 5,838 Cr.
- Current Price ₹ 726
- High / Low ₹ 842 / 330
- Stock P/E 33.4
- Book Value ₹ 113
- Dividend Yield 0.11 %
- ROCE 22.2 %
- ROE 15.7 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 19.4%
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Part of BSE Healthcare BSE SmallCap BSE Allcap Nifty Microcap 250 Nifty Total Market
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|
184 | 213 | 278 | 312 | 391 | 530 | 461 | 570 | 671 | |
166 | 191 | 213 | 213 | 218 | 316 | 332 | 394 | 422 | |
Operating Profit | 17 | 22 | 65 | 98 | 173 | 214 | 129 | 176 | 249 |
OPM % | 9% | 10% | 23% | 32% | 44% | 40% | 28% | 31% | 37% |
7 | 9 | 8 | 11 | 5 | 8 | 9 | 11 | 9 | |
Interest | 12 | 11 | 10 | 7 | 4 | 4 | 3 | 5 | 2 |
Depreciation | 5 | 5 | 5 | 6 | 7 | 10 | 12 | 16 | 18 |
Profit before tax | 8 | 14 | 57 | 96 | 167 | 207 | 123 | 166 | 238 |
Tax % | 30% | 40% | 31% | 24% | 26% | 27% | 27% | 28% | |
6 | 9 | 39 | 73 | 124 | 152 | 90 | 119 | 174 | |
EPS in Rs | 3.87 | 5.96 | 26.93 | 50.11 | 16.89 | 18.86 | 11.17 | 14.80 | 21.68 |
Dividend Payout % | 0% | 0% | 0% | 20% | 3% | 3% | 5% | 5% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 15% |
3 Years: | 13% |
TTM: | 21% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 25% |
3 Years: | -1% |
TTM: | 45% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 26% |
1 Year: | 95% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 26% |
3 Years: | 19% |
Last Year: | 16% |
Balance Sheet
Figures in Rs. Crores
Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|
Equity Capital | 15 | 15 | 15 | 15 | 15 | 16 | 16 | 16 | 16 |
Reserves | 31 | 40 | 79 | 134 | 254 | 600 | 683 | 799 | 890 |
140 | 130 | 90 | 82 | 72 | 27 | 22 | 5 | 6 | |
55 | 60 | 69 | 105 | 105 | 92 | 98 | 100 | 101 | |
Total Liabilities | 241 | 245 | 253 | 336 | 445 | 735 | 820 | 921 | 1,012 |
89 | 91 | 85 | 99 | 100 | 190 | 262 | 310 | 308 | |
CWIP | 36 | 34 | 35 | 40 | 79 | 43 | 68 | 149 | 218 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 25 | 64 | 72 |
117 | 120 | 133 | 197 | 267 | 502 | 466 | 398 | 415 | |
Total Assets | 241 | 245 | 253 | 336 | 445 | 735 | 820 | 921 | 1,012 |
Cash Flows
Figures in Rs. Crores
Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|
27 | 28 | 49 | 117 | 76 | 49 | 64 | 113 | |
-27 | -5 | 5 | -25 | -47 | -60 | -124 | -174 | |
-2 | -20 | -50 | -29 | -15 | 150 | -10 | -22 | |
Net Cash Flow | -2 | 3 | 4 | 62 | 15 | 139 | -70 | -83 |
Ratios
Figures in Rs. Crores
Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|
Debtor Days | 99 | 92 | 79 | 60 | 69 | 79 | 67 | 71 |
Inventory Days | 113 | 85 | 77 | 130 | 206 | 172 | 234 | 140 |
Days Payable | 121 | 112 | 110 | 130 | 145 | 91 | 130 | 98 |
Cash Conversion Cycle | 91 | 64 | 45 | 61 | 130 | 160 | 171 | 114 |
Working Capital Days | 119 | 97 | 96 | 49 | 94 | 132 | 181 | 158 |
ROCE % | 14% | 37% | 50% | 60% | 43% | 19% | 22% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
1d - Earnings call scheduled for May 28, 2025 to discuss Q4 and FY25 financial results.
-
Board Meeting Intimation for Audited Financial Results Of The Company For The Quarter And Year Ended March 31, 2025 And Recommend Dividend, If Any, On The Equity Shares Of The Company For The Financial Year Ended March 31, 2025
2d - Board meeting on May 27 to approve FY25 results and consider dividend; trading window closed till then.
-
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
28 Apr - Supriya Lifescience confirms not a Large Corporate for FY 2024-25 as per SEBI guidelines.
-
Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot
24 Apr - Appointment of two Non-Executive Independent Directors approved via postal ballot on April 23, 2025.
-
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
24 Apr - Appointment of two independent directors approved by postal ballot with over 99% votes.
Annual reports
Concalls
-
Jan 2025Transcript PPT REC
-
Nov 2024Transcript PPT REC
-
Aug 2024Transcript PPT REC
-
Jun 2024Transcript PPT REC
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT REC
-
Aug 2023Transcript PPT REC
-
Jun 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
May 2022TranscriptNotesPPT
-
Feb 2022TranscriptPPT
-
Jan 2022Transcript PPT
Niche Products Offerings[1]
Supriya Lifescience Ltd. has a niche product basket of 40+ APIs and is a global leader in Anti-histamines, anti-allergy, Vitamins, Anti-Asthmatics, & Anesthetics. They utilize a backward-integrated model for 15 products and possess the ability to handle complex chemistries and controlled substances.